Morepen Laboratories Ltd. (BSE: 500288) is a Gurugram, Haryana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹6,773 Cr, it ranks #727 by market cap among the 6,137 Indian listed companies on FinBizNet, and #23 of 86 in Medicinal Chemicals and Botanical Products. At ₹123.54 (as of 25 Oct 2026), the share price is 18.0% below its 52-week high of ₹150.70 and 266.8% above its 52-week low of ₹33.68. The share price is up 154.8% over one year and up 129.6% over three months.
| Current Price | ₹123.54 |
|---|---|
| Market Cap | ₹6,773 Cr |
| BSE Code | 500288 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 70.9 |
| Return on Equity | 7.80% |
| Return on Assets | 3.00% |
| 52-Week Range | ₹33.68 – ₹150.70 |
| 1-Year Price Change | +154.8% |
| 3-Month Price Change | +129.6% |
| Beta (1Y) | 0.69 |
| Dividend Yield | 0.16% |
| Headquarters | Gurugram, Haryana |
| Website | www.morepen.com |
| Revenue | ₹570 Cr |
|---|---|
| Net Profit | ₹56 Cr |
| Net Margin | 9.9% |
| EPS (Basic) | ₹1.03 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, di
1. Pharmaceutical Business-This segment manufactures and sells active pharmaceutical ingredients (APIs), formulations, and home health products.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Morepen Laboratories Ltd. | ₹6,773 Cr | 70.9 | 7.80% | ₹570 Cr | +154.8% |
Listed by market capitalisation. Ratios are shown for context only.
Morepen Laboratories Ltd. is trading at ₹123.54, with a market capitalisation of ₹6,773 Cr.
Morepen Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Morepen Laboratories Ltd. has a P/E of 70.9 and a return on equity of 7.80%.
Morepen Laboratories Ltd. is listed on the BSE under the scrip code 500288.
Morepen Laboratories Ltd.'s share price is up 154.8% over one year and up 129.6% over three months. Its 52-week range is ₹33.68 to ₹150.70.
In Q1 FY27, Morepen Laboratories Ltd. reported revenue of ₹570 Cr and net profit of ₹56 Cr, with basic EPS of ₹1.03 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.